KAYO MOTOR
834058
Zhejiang Zoenn Design
300901
Zhejiang Meorient Commerce & Exhibition Inc.
300795
Fujian Zitian Media Technology
300280
Zhejiang Prulde Electric Appliance
301353
CN Stock MarketDetailed Quotes
301263 Guangdong Taienkang Pharmaceutical
- 15.43
- -0.28-1.78%
Market Closed Dec 13 15:00 CST
6.57BMarket Cap48.68P/E (TTM)
15.80High15.41Low51.33KlotVolume15.66Open15.71Pre Close80.17MTurnover1.95%Turnover Ratio40.93P/E (Static)425.50MShares17.4352wk High3.70P/B4.06BFloat Cap11.3552wk Low18.85Limit Up262.97MShs Float23.69Historical High12.57Limit Down2.48%Amplitude10.91Historical Low0.30Dividend TTM15.62Avg Price28.61KlotAsk1.94%Div YieldTTM100Lot Size21.97KlotBid
Guangdong Taienkang Pharmaceutical News
Taienkang (301263): The Q3 performance was in line with expectations, and all subjects were enrolled in the CKBAII period
Taienkang (301263): Stable operation of core varieties and reasonable product layout under development
Taienkang (301263): Stable core product advantages, successful CKBAII clinical trials
Taienkang (301263): Rapid dosage of health drugs for both sexes and gastrointestinal use is expected to reach an inflection point
Taienkang (301263): The main business is developing steadily, and the clinical progress of CKBA's innovative drug is progressing smoothly
Taienkang (301263): Core varieties build existing advantages CKBA opens up future space
Taienkang (301263): Performance is under short-term pressure due to capacity upgrades, medium- to long-term layout can be expected in the future
Taienkang (301263): Short-term performance under pressure, continuous investment in R&D to provide long-term growth
Taienkang (301263): Core products continue to increase both revenue and net profit
Taienkang (301263): Continued high growth in performance and significant volume of core products
Taienkang (301263) 2023 Interim Report Review Report: Steady Growth in Performance, Good Competition Pattern for Core Products
Tyne Kang (301263): CKBA Ointment for Vitiligo Indications Phase II Clinical Approval Company Executives Plan to Increase Holding Show Confidence in Development
Research Report Nugge丨Huaxi Securities: Taiencang Acquires Thailand's Complete Set of Production Technology to Solve Production Capacity Bottlenecks, Adding New Driving Force to Future Growth
Taiencang (301263): Acquisition of Thailand's complete production technology to solve production capacity bottlenecks and add new driving force for future growth
Taienkang (301263): Continued release of core products, rich R&D pipelines, opening up space for long-term growth
Review of Taienkang's (301263) Annual Report and Quarterly Report: Performance is in line with expectations, and research pipelines are abundant
Review of the Taienkang (301263) incident: It is proposed to acquire 50% of Bochuang Park's shares to lay out CKBA skin innovation drugs
Taienkang (301263): Acquired 50% of Bochuang Park's shares to obtain self-exemption of innovative drug pipelines
Taienkang (301263) 2022 performance forecast review: The high annual profit growth rate is in line with expectations, and the rapid release of wool products
Tynkang (301263) Annual Report Performance Forecast Review: High Performance Growth Meets Expectations and Stomach Market Shortage Affects Performance
